Compare · MCK vs SCNX
MCK vs SCNX
Side-by-side comparison of McKesson Corporation (MCK) and Scienture Holdings Inc. (SCNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MCK and SCNX operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- MCK is the larger of the two at $88.33B, about 5485.6x SCNX ($16.1M).
- Over the past year, MCK is up 1.9% and SCNX is down 54.4% - MCK leads by 56.4 points.
- MCK has been more active in the news (31 items in the past 4 weeks vs 4 for SCNX).
- MCK has more recent analyst coverage (25 ratings vs 0 for SCNX).
- Company
- McKesson Corporation
- Scienture Holdings Inc.
- Price
- $735.16-1.00%
- $0.39-5.00%
- Market cap
- $88.33B
- $16.1M
- 1M return
- -9.81%
- +1.31%
- 1Y return
- +1.94%
- -54.42%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 31
- 4
- Recent ratings
- 25
- 0
McKesson Corporation
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Latest MCK
- SEC Form 4 filed by EVP & CFO Cheung Kenny K
- SEC Form 3 filed by new insider Cheung Kenny K
- SEC Form SD filed by McKesson Corporation
- EVP and Chief Legal Officer Lau Michele sold $2,701,870 worth of shares (3,550 units at $761.09) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 3,247 units (SEC Form 4)
- EVP & CFO Vitalone Britt J. converted options into 1,476 shares and covered exercise/tax liability with 581 shares, increasing direct ownership by 4% to 21,953 units (SEC Form 4)
- Chief Executive Officer Tyler Brian S. converted options into 4,579 shares and covered exercise/tax liability with 1,831 shares, increasing direct ownership by 11% to 27,774 units (SEC Form 4)
- EVP & Chief HR Officer Smith Leann B converted options into 679 shares and covered exercise/tax liability with 268 shares, increasing direct ownership by 7% to 6,608 units (SEC Form 4)
- EVP, Chief Strategy & BDO Rodgers Thomas L covered exercise/tax liability with 234 shares, sold $1,817,483 worth of shares (2,388 units at $761.09) as part of a pre-agreed trading plan and converted options into 594 shares, decreasing direct ownership by 40% to 3,090 units (SEC Form 4)
- EVP, CIO and CTO Fraga Francisco converted options into 136 shares and covered exercise/tax liability with 54 shares, increasing direct ownership by 1% to 6,210 units (SEC Form 4)
- SVP, Controller & CAO Rutledge Napoleon B Jr converted options into 136 shares and covered exercise/tax liability with 41 shares, increasing direct ownership by 14% to 765 units (SEC Form 4)
Latest SCNX
- Scienture Holdings Inc. filed SEC Form 8-K: Leadership Update
- Scienture Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
- SEC Form 10-Q filed by Scienture Holdings Inc.
- Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
- SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
- Scienture Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Scienture Holdings Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Amendment: SEC Form 10-K/A filed by Scienture Holdings Inc.
- Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement